The high acceptance rates of these interventions demonstrate the key role in optimizing patient care that clinical oncology pharmacists with access to medical records play.
Nicole Bentivegna, PharmD, BCOP
Advertisement
Articles by Nicole Bentivegna, PharmD, BCOP
The drug solidifies its place as a first-line treatment option in AML.
The program develops patient-centered oncology pharmacists through comprehensive training.
Advancements include novel combination therapies and improved diagnostic techniques.
An overview of current FDA-approved ROS1-targeted therapies.
Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.
Advertisement
Latest Updated Articles
Shaping the Future of Oncology Pharmacy Through the NCODA Medically Integrated Oncology Pharmacy Residency ProgramPublished: December 27th 2024 | Updated:
Quizartinib in FLT3-ITD–Positive Acute Myeloid Leukemia: A New Era in Targeted TherapyPublished: February 25th 2025 | Updated:
The Evolution of PI3K Inhibitors in the Treatment of Breast CancerPublished: October 22nd 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5
